25 results on '"Teixido, C."'
Search Results
2. 152P Role of occupation in patients with non-small cell lung cancer (NSCLC) in Spain: Data from the SCAN study
3. EP08.02-102 Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
4. 1659TiP A Spanish observational study for MOLecular characterization of THYroid carcinoma: MOLTHY Project – TTCC-2020-02
5. MA07.07 Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
6. OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
7. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
8. 138P Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes
9. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
10. 1268P Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
11. 182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study
12. EP1.01-41 Feasibility of EBUS-TBNA Cytologies for an Extensive Assessment of Predictive Biomarkers in Lung Cancer
13. P1.01-43 Programmed-Death Ligand 1 Spectrum in a Large Cohort of Genetically Characterized Non-Small Cell Lung Cancer Patients
14. P2.03-17 Optimization of an Ex-Vivo Preclinical Model for Drug Testing
15. P2.04-61 Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity
16. P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC
17. P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
18. P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
19. P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
20. P3.01-045 Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution
21. 514 Hypoxia inducible factor (HIF)-1a expression levels and p53 mutations are prognostic factors for survival in breast cancer patients treated with neoadjuvant chemotherapy
22. 254 Molecular analysis in breast cancer: correlation with Immunohistochemical classification and pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC)
23. 478 Pharmacological disruption of the Astrocytic Elevated Gene-1 (AEG1) in anticancer intervention: PB0412_3 (PB03) as a first-in-class AEG1 interacting agent
24. Can we Do Better with Our Current Therapies for Nsclc? the Spanish Lung Cancer Group Approach
25. 676 HER3 Expression in Human Breast Carcinomas is Associated With Tumor Size and Estrogen Receptor Status
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.